Temozolomide resistance in glioblastoma multiforme

Sang Lee

Research output: Contribution to journalReview articlepeer-review

705 Scopus citations


Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas. However, at least 50% of TMZ treated patients do not respond to TMZ. This is due primarily to the over-expression of O6-methylguanine methyltransferase (MGMT) and/or lack of a DNA repair pathway in GBM cells. Multiple GBM cell lines are known to contain TMZ resistant cells and several acquired TMZ resistant GBM cell lines have been developed for use in experiments designed to define the mechanism of TMZ resistance and the testing of potential therapeutics. However, the characteristics of intrinsic and adaptive TMZ resistant GBM cells have not been systemically compared. This article reviews the characteristics and mechanisms of TMZ resistance in natural and adapted TMZ resistant GBM cell lines. It also summarizes potential treatment options for TMZ resistant GBMs.

Original languageEnglish (US)
Pages (from-to)198-210
Number of pages13
JournalGenes and Diseases
Issue number3
StatePublished - Sep 1 2016

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Genetics(clinical)
  • Cell Biology


Dive into the research topics of 'Temozolomide resistance in glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this